 Michael Bishop
Concepts (172)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteosarcoma | 15 | 2024 | 45 | 4.760 |
Why?
| | Bone Neoplasms | 17 | 2024 | 178 | 4.260 |
Why?
| | Sarcoma, Ewing | 6 | 2024 | 27 | 1.990 |
Why?
| | Neuroblastoma | 5 | 2021 | 51 | 1.480 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2021 | 225 | 1.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1000 | 0.950 |
Why?
| | Induction Chemotherapy | 4 | 2021 | 59 | 0.870 |
Why?
| | Child, Preschool | 18 | 2024 | 3965 | 0.760 |
Why?
| | Child | 26 | 2024 | 6976 | 0.750 |
Why?
| | Adolescent | 25 | 2024 | 6489 | 0.750 |
Why?
| | Young Adult | 19 | 2023 | 4114 | 0.600 |
Why?
| | Nuclear Proteins | 2 | 2024 | 238 | 0.590 |
Why?
| | Neoplasms | 7 | 2022 | 1250 | 0.580 |
Why?
| | Radionuclide Imaging | 1 | 2016 | 116 | 0.500 |
Why?
| | Sarcoma | 3 | 2024 | 65 | 0.500 |
Why?
| | Immunotherapy | 2 | 2021 | 236 | 0.480 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 122 | 0.470 |
Why?
| | Desmoplastic Small Round Cell Tumor | 3 | 2019 | 4 | 0.460 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 582 | 0.460 |
Why?
| | Lung Neoplasms | 2 | 2020 | 599 | 0.460 |
Why?
| | Male | 28 | 2024 | 25991 | 0.450 |
Why?
| | Prognosis | 7 | 2021 | 1979 | 0.450 |
Why?
| | Adult | 21 | 2022 | 13636 | 0.440 |
Why?
| | Oncogene Proteins | 1 | 2014 | 16 | 0.440 |
Why?
| | Female | 28 | 2024 | 27181 | 0.430 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2014 | 50 | 0.420 |
Why?
| | Survivors | 4 | 2022 | 128 | 0.400 |
Why?
| | Humans | 38 | 2024 | 50673 | 0.400 |
Why?
| | Bone and Bones | 1 | 2016 | 481 | 0.390 |
Why?
| | Retrospective Studies | 14 | 2024 | 6294 | 0.370 |
Why?
| | Liver Neoplasms | 2 | 2018 | 328 | 0.360 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2021 | 56 | 0.350 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2021 | 626 | 0.330 |
Why?
| | Peritoneal Neoplasms | 3 | 2019 | 63 | 0.320 |
Why?
| | Hyperthermia, Induced | 2 | 2019 | 115 | 0.280 |
Why?
| | Cohort Studies | 6 | 2020 | 1455 | 0.270 |
Why?
| | Pain | 2 | 2020 | 386 | 0.270 |
Why?
| | Cognition Disorders | 2 | 2020 | 212 | 0.260 |
Why?
| | Methotrexate | 2 | 2017 | 77 | 0.250 |
Why?
| | Follow-Up Studies | 6 | 2021 | 2246 | 0.250 |
Why?
| | Combined Modality Therapy | 4 | 2020 | 642 | 0.240 |
Why?
| | Survival Rate | 4 | 2020 | 907 | 0.230 |
Why?
| | Wilms Tumor | 1 | 2024 | 18 | 0.230 |
Why?
| | Rhabdoid Tumor | 1 | 2024 | 12 | 0.230 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2024 | 11 | 0.220 |
Why?
| | Treatment Outcome | 7 | 2024 | 5294 | 0.220 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 119 | 0.210 |
Why?
| | Risk Factors | 6 | 2021 | 3731 | 0.200 |
Why?
| | Kidney Neoplasms | 1 | 2024 | 171 | 0.200 |
Why?
| | DNA Helicases | 1 | 2024 | 147 | 0.200 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2019 | 121 | 0.200 |
Why?
| | Interleukin-2 | 1 | 2021 | 71 | 0.190 |
Why?
| | Prospective Studies | 4 | 2021 | 2395 | 0.190 |
Why?
| | Infant | 6 | 2024 | 3656 | 0.190 |
Why?
| | Survival Analysis | 2 | 2020 | 661 | 0.180 |
Why?
| | Hypothyroidism | 1 | 2021 | 56 | 0.180 |
Why?
| | Transcription Factors | 1 | 2024 | 566 | 0.180 |
Why?
| | Phthalazines | 1 | 2020 | 20 | 0.170 |
Why?
| | Salvage Therapy | 1 | 2021 | 137 | 0.170 |
Why?
| | Central Nervous System Neoplasms | 1 | 2021 | 62 | 0.170 |
Why?
| | Quality of Life | 4 | 2021 | 858 | 0.170 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 181 | 0.170 |
Why?
| | Leydig Cells | 1 | 2019 | 7 | 0.160 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2023 | 189 | 0.160 |
Why?
| | Radiotherapy | 2 | 2017 | 125 | 0.160 |
Why?
| | Epigenomics | 1 | 2019 | 65 | 0.160 |
Why?
| | Brachytherapy | 1 | 2019 | 46 | 0.160 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2018 | 6 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 315 | 0.150 |
Why?
| | Alanine Transaminase | 1 | 2018 | 119 | 0.150 |
Why?
| | Anesthetics | 1 | 2018 | 36 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 2 | 2024 | 511 | 0.150 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 481 | 0.140 |
Why?
| | Chronic Disease | 1 | 2020 | 576 | 0.140 |
Why?
| | Risk Assessment | 5 | 2021 | 1271 | 0.140 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2017 | 5 | 0.140 |
Why?
| | Hand-Foot Syndrome | 1 | 2017 | 1 | 0.140 |
Why?
| | Genomics | 1 | 2019 | 279 | 0.140 |
Why?
| | Thoracic Wall | 1 | 2017 | 9 | 0.140 |
Why?
| | Chile | 1 | 2017 | 4 | 0.140 |
Why?
| | Thoracic Neoplasms | 1 | 2017 | 13 | 0.140 |
Why?
| | Cytarabine | 1 | 2017 | 37 | 0.140 |
Why?
| | Pain Management | 1 | 2018 | 180 | 0.140 |
Why?
| | Cost of Illness | 1 | 2017 | 115 | 0.140 |
Why?
| | Health Resources | 1 | 2017 | 74 | 0.130 |
Why?
| | Karyotype | 1 | 2016 | 17 | 0.130 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2016 | 35 | 0.130 |
Why?
| | Radiation Injuries | 1 | 2017 | 112 | 0.130 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 1403 | 0.120 |
Why?
| | Hematologic Neoplasms | 1 | 2017 | 99 | 0.120 |
Why?
| | Urogenital Neoplasms | 1 | 2015 | 9 | 0.120 |
Why?
| | Neurotoxicity Syndromes | 1 | 2016 | 45 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 416 | 0.120 |
Why?
| | Forecasting | 1 | 2015 | 145 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2016 | 279 | 0.110 |
Why?
| | Organ Sparing Treatments | 1 | 2014 | 56 | 0.110 |
Why?
| | Disease Management | 1 | 2015 | 179 | 0.110 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 1613 | 0.110 |
Why?
| | Rats | 1 | 2020 | 3302 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2014 | 55 | 0.100 |
Why?
| | Cognition | 1 | 2016 | 346 | 0.100 |
Why?
| | United States | 3 | 2018 | 5012 | 0.100 |
Why?
| | Prevalence | 3 | 2021 | 975 | 0.100 |
Why?
| | Infant, Newborn | 2 | 2017 | 2755 | 0.090 |
Why?
| | Neoplasm Staging | 2 | 2023 | 743 | 0.080 |
Why?
| | Animals | 2 | 2020 | 13156 | 0.070 |
Why?
| | Time Factors | 3 | 2021 | 2948 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2019 | 442 | 0.060 |
Why?
| | Age Factors | 2 | 2021 | 1120 | 0.060 |
Why?
| | Middle Aged | 5 | 2019 | 12648 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2024 | 1037 | 0.060 |
Why?
| | Databases, Factual | 2 | 2018 | 676 | 0.060 |
Why?
| | Germ-Line Mutation | 1 | 2024 | 61 | 0.060 |
Why?
| | Femoral Neoplasms | 1 | 2024 | 8 | 0.060 |
Why?
| | Nephrectomy | 1 | 2024 | 77 | 0.060 |
Why?
| | Limb Salvage | 1 | 2024 | 40 | 0.060 |
Why?
| | Femur | 1 | 2024 | 130 | 0.050 |
Why?
| | Surgical Wound Infection | 1 | 2024 | 117 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2023 | 204 | 0.050 |
Why?
| | Tumor Burden | 1 | 2021 | 130 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2023 | 293 | 0.050 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 1173 | 0.050 |
Why?
| | Ifosfamide | 1 | 2021 | 11 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2021 | 39 | 0.040 |
Why?
| | Vincristine | 1 | 2021 | 82 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2021 | 167 | 0.040 |
Why?
| | Length of Stay | 1 | 2024 | 634 | 0.040 |
Why?
| | Gangliosides | 1 | 2019 | 4 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2019 | 49 | 0.040 |
Why?
| | Anthracyclines | 1 | 2020 | 29 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 205 | 0.040 |
Why?
| | Doxorubicin | 1 | 2021 | 236 | 0.040 |
Why?
| | Testosterone | 1 | 2019 | 146 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 107 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 488 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 64 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 463 | 0.040 |
Why?
| | Rare Diseases | 1 | 2018 | 43 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 372 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 212 | 0.040 |
Why?
| | Tennessee | 1 | 2017 | 37 | 0.040 |
Why?
| | Parity | 1 | 2017 | 43 | 0.030 |
Why?
| | Radiodermatitis | 1 | 2017 | 5 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2018 | 161 | 0.030 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2017 | 73 | 0.030 |
Why?
| | Ovary | 1 | 2017 | 114 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 136 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 173 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2021 | 461 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 213 | 0.030 |
Why?
| | Proteomics | 1 | 2019 | 317 | 0.030 |
Why?
| | Scoliosis | 1 | 2017 | 60 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 373 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2017 | 162 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 551 | 0.030 |
Why?
| | Osteoporosis | 1 | 2017 | 156 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 584 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 552 | 0.030 |
Why?
| | Memory | 1 | 2016 | 114 | 0.030 |
Why?
| | Executive Function | 1 | 2016 | 76 | 0.030 |
Why?
| | Attention | 1 | 2016 | 172 | 0.030 |
Why?
| | Morbidity | 1 | 2015 | 130 | 0.030 |
Why?
| | Extremities | 1 | 2014 | 30 | 0.030 |
Why?
| | Emotions | 1 | 2016 | 168 | 0.030 |
Why?
| | Body Mass Index | 1 | 2017 | 675 | 0.030 |
Why?
| | Biopsy | 1 | 2016 | 589 | 0.030 |
Why?
| | Incidence | 1 | 2017 | 1036 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2017 | 982 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1376 | 0.030 |
Why?
| | Mutation | 1 | 2019 | 1280 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2016 | 1157 | 0.020 |
Why?
| | Mice | 1 | 2020 | 5677 | 0.020 |
Why?
|
|
Bishop's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|